CACNG2
ENSG00000166862
Target class
Auxiliary transport protein
Chromosome
22
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNG2
- Gene name
- Calcium voltage-gated channel auxiliary subunit gamma 2
- Gene symbol
- CACNG2
- Protein name
- Voltage-dependent calcium channel gamma-2 subunit (Neuronal voltage-gated calcium channel gamma-2 subunit) (Transmembrane AMPAR regulatory protein gamma-2) (TARP gamma-2)
- stargazin
- MGC138502
- MGC138504
- Gene biotype
- Protein coding
- Gene family
- Calcium channel auxiliary gamma subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 13
- Highest tissue expression
- 18.03
- Tissue specificity (Gini)
- 0.874
- Tissue specificity (tau)
- 0.95
- KEGG gene identifiers
- hsa:10369
- Protein interaction confidence
- 0.801704
- Protein interaction partners
- 81
- R-HSA-112308
- R-HSA-399719
- R-HSA-5682910
- End position
- 36703752
- Start position
- 36560857
- Chromosome
- 22
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein. Synapse, synaptosome .
- Tissue specificity (tau)
- 0.950052
- Expression inequality (Gini)
- 0.874014
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 18.03
- Brain - Cerebellum
- 17.66
- Brain - Frontal Cortex (BA9)
- 6.42
- Brain - Cortex
- 5.35
- Brain - Anterior cingulate cortex (BA24)
- 3.33
Expression in transcripts per million
- Brain - Cerebellar Hemisphere18.03
- Brain - Cerebellum17.66
- Brain - Frontal Cortex (BA9)6.42
- Brain - Cortex5.35
- Brain - Anterior cingulate cortex (BA24)3.33
- Brain - Hypothalamus2.76
- Brain - Nucleus accumbens (basal ganglia)1.8
- Brain - Caudate (basal ganglia)1.76
- Brain - Amygdala1.75
- Pituitary1.56
- Brain - Putamen (basal ganglia)1.45
- Brain - Hippocampus1.22
- Brain - Substantia nigra1.22
- Brain - Spinal cord (cervical c-1)0.88
- Testis0.23
- Colon - Sigmoid0.03
- Adipose - Visceral (Omentum)0.02
- Stomach0.02
- Fallopian Tube0.02
- Adrenal Gland0.02
- Cervix - Ectocervix0.02
- Esophagus - Gastroesophageal Junction0.01
- Small Intestine - Terminal Ileum0.01
- Esophagus - Muscularis0.01
- Colon - Transverse0.01
And 29 more, listed on the interactive page.
- GO:0005886
- GO:0005891
- GO:0030666
- GO:0005245
- GO:0005515
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker